WuXi Biologics has announced it has secured a key regulatory milestone after its MFG8 drug substance manufacturing facility in Hebei, China, successfully passed a pre-license inspection (PLI) by the US Food and Drug Administration (FDA), paving the way for commercial production of a potential blockbuster autoimmune therapy.
The seven-day inspection, conducted by three FDA inspectors, assessed the facility's quality management system and biologics drug substance manufacturing operations.
A successful PLI is a critical step ahead of product approval, confirming that a manufacturing site is capable of consistently producing medicines in compliance with cGMP requirements.
For CDMOs, FDA PLI approvals are an important differentiator, demonstrating regulatory readiness and providing biopharmaceutical companies with confidence that commercial supply can be scaled following product approval.
MFG8 forms part of WuXi Biologics' global manufacturing network and is equipped with twelve 4000 L single-use bioreactors.
The facility uses the company's "scale-out" manufacturing strategy, enabling flexible commercial production capacities ranging from 4000 L to 20,000 L while reducing the complexity associated with traditional scale-up approaches.
The site also incorporates digital manufacturing technologies, rooftop solar photovoltaics and sustainability-focused design features intended to reduce carbon emissions, improve resource efficiency and support recycling initiatives.
Chris Chen, CEO of WuXi Biologics, said the successful inspection reflected the company's continued investment in quality systems and its ability to support partners through commercial manufacturing.
"MFG8's successful FDA Pre-License Inspection pass is a strong testament to WuXi Biologics' commitment to global quality and compliance standards."
We are pleased to help bring this potential blockbuster autoimmune therapy to patients through our high-quality manufacturing capabilities.
The latest approval further extends the company's regulatory track record. As of the end of 2025, WuXi Biologics had completed 46 regulatory inspections, including 22 conducted by the FDA and the European Medicines Agency (EMA), while securing 136 facility licence approvals worldwide.
The company added that it has maintained a 100% success rate for FDA pre-license inspections and has completed more than 1800 GMP quality audits by customers, including more than 230 performed by EU Qualified Persons.
